Member Info for EmeraldCarrots

Moab.

"The Grail trial with England's National Health Service (NHS) failed to meet its primary endpoint of demonstrating a "statistically significant Stage III-IV reduction" in cancer detection rates. ".

Are you saying in stage III to IV cancers there are little or no CTC's to detect? I was under the impression stage 3 and 4 cancers are advanced.

Please enlighted me. The www and A.I seems to say you are completely wrong. Obviously if there are no circulating tumour cells in the blood there is no way to catch them with the parsortix machine. I was under the impression there would be CTC's, especially ig the cancer was at stage 4.

https://www.fool.com/investing/2026/02/23/heres-why-grail-stock-slumped-again-today/

A.I.

Integrating the Parsortix system (manufactured by CelLBxHealth, formerly ANGLE plc) could address several of the limitations currently facing Grail Inc. and its Galleri test. Following Grail’s recent 2026 report that its trial failed to meet the primary goal of reducing late-stage cancer diagnoses, the addition of a complementary technology like Parsortix could offer several strategic benefits:

1. Increased Diagnostic Sensitivity

Dual Analysis: While Grail focuses on cell-free DNA (cfDNA) fragments, Parsortix captures Circulating Tumour Cells (CTCs). Research suggests a "tandem" approach can significantly improve detection rates. For example, in lung cancer studies, combining both biomarkers increased sensitivity to 95%, outperforming either method alone.

Catching "DNA-Silent" Cancers: Some early-stage or specific cancer subtypes (like those driven by certain mutations or fusions) may not shed enough cfDNA to be detected by Grail's methylation platform. Parsortix can capture the intact cells these tumors release, filling a critical gap in detection.

2. Deeper "Multi-Omic" Insights

Beyond DNA: Grail's test is limited to genetic and epigenetic (methylation) data. Because Parsortix harvests live, intact cells, it enables RNA and protein sequencing.

Treatment Selection: This allows Grail to move beyond just "detecting" cancer to helping doctors choose specific therapies based on the protein expression (like PD-L1 or HER2) found on the captured cells.

3. Improved Accuracy in Early Stages

Complementary Information: cfDNA represents a "global picture" of cell death throughout the body, while CTCs provide a snapshot of viable, aggressive cells that are actively trying to spread.

Reducing False Negatives: Integrating CTC analysis could help Grail catch the stage I and II cancers that its current cfDNA-only approach sometimes misses due to low signal abundance.

4. Technical and Operational Synergies

Standardised Workflow: Both technologies can potentially use the same blood draw. Studies have shown that blood collected in preservative tubes (like CellSave) is stable for up to 96 hours, allowing a single sample to be shipped to a central lab for both cfDNA and CTC analysis.

Alignment with Partners: Angle has already begun aligning Parsortix with Illumina's NGS platforms—the same sequencing technology Grail was built upon—making a technical integration more feasible..

A.I.

Integrating the Parsortix system (manufactured by CelLBxHealth, formerly ANGLE plc) could address several of the limitations currently facing Grail Inc. and its Galleri test. Following Grail’s recent 2026 report that its trial failed to meet the primary goal of reducing late-stage cancer diagnoses, the addition of a complementary technology like Parsortix could offer several strategic benefits:

1. Increased Diagnostic Sensitivity

Dual Analysis: While Grail focuses on cell-free DNA (cfDNA) fragments, Parsortix captures Circulating Tumour Cells (CTCs). Research suggests a "tandem" approach can significantly improve detection rates. For example, in lung cancer studies, combining both biomarkers increased sensitivity to 95%, outperforming either method alone.

Catching "DNA-Silent" Cancers: Some early-stage or specific cancer subtypes (like those driven by certain mutations or fusions) may not shed enough cfDNA to be detected by Grail's methylation platform. Parsortix can capture the intact cells these tumors release, filling a critical gap in detection.

2. Deeper "Multi-Omic" Insights

Beyond DNA: Grail's test is limited to genetic and epigenetic (methylation) data. Because Parsortix harvests live, intact cells, it enables RNA and protein sequencing.

Treatment Selection: This allows Grail to move beyond just "detecting" cancer to helping doctors choose specific therapies based on the protein expression (like PD-L1 or HER2) found on the captured cells.

3. Improved Accuracy in Early Stages

Complementary Information: cfDNA represents a "global picture" of cell death throughout the body, while CTCs provide a snapshot of viable, aggressive cells that are actively trying to spread.

Reducing False Negatives: Integrating CTC analysis could help Grail catch the stage I and II cancers that its current cfDNA-only approach sometimes misses due to low signal abundance.

4. Technical and Operational Synergies

Standardised Workflow: Both technologies can potentially use the same blood draw. Studies have shown that blood collected in preservative tubes (like CellSave) is stable for up to 96 hours, allowing a single sample to be shipped to a central lab for both cfDNA and CTC analysis.

Alignment with Partners: Angle has already begun aligning Parsortix with Illumina's NGS platforms—the same sequencing technology Grail was built upon—making a technical integration more feasible.

Https://www.globenewswire.com/news-release/2026/02/20/3242117/0/en/gral-alert-investigation-launched-into-grail-inc-rgrd-law-attorneys-encourage-investors-and-potential-witnesses-to-contact-law-firm.html

https://markets.financialcontent.com/stocks/article/bizwire-2026-2-20-grail-shareholders-are-encouraged-to-reach-out-to-johnson-fistel-for-more-information-about-potentially-recovering-their-losses

==================

Seems some investors are livid about the news and 50% share price drop. Frankly I'm no expert but it has been said that the info needed to make these test work may not be available from analysing Cell-free DNA (cfDNA) in Blood. You can't find informsation that does not exist no matter how hard you look. It seems this may be the case here?

Cellbxhealths parsortix machine can catch live, intact, uncontaminated circulating tumor cells (CTC's) from a blood sample of someone who has cancer that is trying to spread. So use the Grail Inc. "tech" to do the same analysis on these as they do on the blood sample. Then you have Cellbxhealths so called "dual analysis" with teeth. This is what the UK's NHS should be piloting, and Cellbxhealth DID meet NHS representatives to discuss this very idea last November in the UK.

All IMHO.

Https://www.bbc.co.uk/news/articles/cwyx7580xvyo

IMHO Grail need to use Cellbxhealths "dual analysis" and apply their tech. This share price could be 10p or more if this obvious route to obtain significantly more information is taken. Cellbxhealth HAVE alresdy spoken to the NHS about this (last Nivember). Why don't Grail try to buy Cellbxhealth?

All IMHO.

To catch any circulating tumor cells (CTC's) that may or may not be found surely they would be on a winner. Adding the two types of analysis together (dual analysis) would surely give far better results. The Grail test looks for DNA fragments in a blood sample. Clearly not enough information can be found. Adding any CTC's (that may of may not be found in that sample) would surely make the test far more sensitive? It seems to me Grail simply cant obtain the information they want from CfDna, if it even exists. Looking for fragmants of DNA in the blood AND looking for live, intact, uncontaminated CTC's to test would seem to be the obvious answer.

All IMHO.

From the BBC article:-

"The blood test searches for fragments of DNA – or genetic code – that have escaped from tumours and entered the bloodstream.

The vision is to detect up to 50 types of cancer before the person has any symptoms.

At the start of the clinical trial, NHS England described the test as "the beginning of a revolution".

https://www.bbc.co.uk/news/articles/cwyx7580xvyo

A.I.

The Outlook: Why it might still grow

Despite these hurdles, Parsortix is gaining traction in research and clinical trials because ctDNA cannot tell you everything. Unlike DNA fragments, a whole cell captured by Parsortix allows doctors to see protein expression (like PD-L1 or HER2) and cell morphology, which are critical for choosing targeted therapies.

============================

Grail share price went down 51% on Friday 20th Feb.

- It seems CfDna is not "delivering the goods", or should one say the information:-

===========================

Cell-free DNA (cfDNA) in Blood: The Galleri test analyzes fragments of DNA that have escaped from tumors and entered the bloodstream.

Methylation Patterns: GRAIL uses a targeted methylation-based technology to detect chemical modifications (methylation) in the DNA, which act as markers for cancer.

Genome Methylation Sites: Their technology scans approximately 30 million methylation sites across the genome to identify cancer signals.

Machine Learning Algorithms: GRAIL applies advanced machine learning and data science, including deep learning models on platforms like Google Cloud's Vertex AI, to analyze non-linear relationships between methylation density and the presence of cancer.

Large-Scale Clinical Studies: Data is generated from major clinical studies, such as the NHS-Galleri trial (142,000+ participants) and the Circulating Cell-free Genome Atlas (CCGA) study.

Yes,

CelLBxHealth (formerly ANGLE plc) is actively engaged with the NHS through clinical studies and emerging strategic discussions aimed at integrating their technology into standard care.

Key areas of involvement include:

Clinical Studies: The Parsortix® system is already being used in several leading UK cancer research centres. For example, University College Hospitals NHS Foundation Trust has a consultant urological surgeon, Prof. Greg L Shaw, who serves as a medical advisor to CelLBxHealth.

"Blood Test First" Initiative: The company recently engaged in "very serious discussions" with the NHS following the announcement of the Blood Test First initiative for lung cancer. This programme aims to use blood tests to identify specific treatments for lung cancer patients earlier in the diagnostic process.

NHS 10-Year Health Plan: CelLBxHealth is progressing discussions to establish major clinical studies that would formally assess the benefits of their CTC analysis, with the goal of clinical adoption as part of the NHS 10-Year Health Plan.

Research Summaries: The Health Research Authority (HRA) has published summaries of research involving the Parsortix system, focusing on its potential to replace invasive surgical biopsies with simple blood samples.

AI responses may include mistakes. For financial advice, consult a professional. Learn more

The analysis Grail do is Cell-Free DNA (cfDNA) and the news is not good by the looks (Gail down 50%). Cellbxhealth analyse both Circulating Tumour Cell DNA (CTC-DNA) AND Cell-Free DNA (cfDNA) at the same time from the same blood sample. They use their Parsortix to cath live, intact, uncontaminated cancer cells for analysis. May get Grain knocking on the door soon.........................

All IMHO.

I think it was. This combines the analysis of Circulating Tumour Cell DNA (CTC-DNA) and Cell-Free DNA (cfDNA) from a single blood sample. Cellbxheath ALREADY, working with Illumina, have an assay for lung cancer. It has neen available since about last November. I think Cellbxhealth proposed the NHS run a pilot study.............

All IMHO.

https://cellbxhealth.com/laboratory-services/ngs/

Grail are down 50%! Looks like even cfDNA (Cell-free DNA analysis from blood) cannot obtain the information needed. Does the necessary information even exist in CfDna? This could be beneficial to Cellbxhealth Plc. Parsortix can catch CtDna (circulating tumor DNA), whole, live, intact uncontamonated cancer cells for analysis. And Myriad Genetics have been collaborating with Cellbxheath sine last August to see if using Parsortix to catch the cells, and analyse them, can give the information needed..................................

Also if CfDna simply does not contain the information (as some suspect) then the likes of Grail will need something else to analyse.......... CTDNA? And how are they going to catch the cells????????????????? It ain't easy!

All IMHO.

Plus more hospitals in Ireland?, how's the Saudi Arabia evaluation going?, Italy?, France?, Germany?, other Countries in the World??? The silence is deafening. If I were David Nugent I would be checking out what the sales staff have been doing and what they intend to do. URGENTLY. This company, as far as I am concerned needs a new person with the title of say "European Sales Director". Someone who is fluent in German, French and Italian maybe. Someone who has experience selling medical machines to hospitals in the EU. The clock is ticking and thus far the sales side has not performed as far as I can see.

Al IMHO.

Ward".

Ok, thats not good.

By the way we use an antibiotic that in rare cases might make you baby deaf.

We dont have the machine to test for this though as it costs £2k and each test is about £100.

Is that ok with you?..........................................!!!!!!!!!!!!!!!!!!!!

https://genedrive.com/product/mt-rnr1-id-kit/

Ok, thats not good.

By the way we use an antibiotic that in rare cases might make you baby deaf.

We dont have the machine to test for this though as it costs £2k and each test is about £100.

Is that ok with you?..........................................!!!!!!!!!!!!!!!!!!!!

https://genedrive.com/product/mt-rnr1-id-kit/

Ok, thats not good.

By the way we use an antibiotic that in rare cases might make you baby deaf.

We dont have the machine to test for this though as it costs £2k and each test is about £100.

Is that ok with you?..........................................!!!!!!!!!!!!!!!!!!!!

Methinks. I also think their sales team could do a lot better. I would describe the sales performance as woeful.

=========================

For the MT-RNR1 there should be a HUGE DEMAND (if from no-one else the PARENTS) of babies in neonatal care.

It is ridiculous.

Methinks. I also think their sales team could do a lot better. I would describe the sales performance as woeful.

All IMHO.

One wonders how the collaboration with Myriad genetics is coming along. They have had about 6 months so far to evaluate the potential use of Cellbxhealths Parsortix machine in their comprehensive DNA/RNA cancer tests. If they decide to use parsortix in any test they offer the sp will IMHO explode!

All IMHO.

Blood, you DO have cancer. I believe that is a true statement. That is what Cellbxhealths parsortix machine is designed to catch from a liquid sample. There simply must be more market £ share to get with the right approach. Something huge could break at any moment.

All IMHO.

Alternative to cervical screening".

"Key Insights on CTCs and Menstrual Blood:

Presence in Gynaecological Cancers: Studies have shown that CTCs are present in the blood of 75% of patients with endometrial cancer, even in early stages. Because menstrual blood involves the shedding of the uterine lining, it naturally carries cells from these areas.

Diagnostic Potential: Researchers are developing at-home menstrual blood tests as a non-invasive alternative for screening cervical cancer and other conditions. A 2026 study found that testing menstrual blood for HPV and cancerous markers had comparable accuracy to traditional clinician-collected cervical samples.

Circulating Endometrial Cells (CECs): In women with endometriosis, cells similar to CTCs (called CECs) are found in the blood. These cells migrate from the uterus to other parts of the body, providing a potential biomarker for non-invasive diagnosis.

Stem Cells vs. Tumour Cells: Menstrual blood is also rich in mesenchymal stem cells, which are healthy, self-renewing cells. While these are not "tumour cells," they share some migratory properties with CTCs and are being studied for cancer therapies."

https://www.bbc.co.uk/news/articles/cly90d21qexo